Developers
Zhigang Lu, Jingjing Xie, Guojin Wu, Philipp E Scherer, Cheng Cheng Zhang, etc.
Description of the technology
New therapeutic approaches are needed to treat leukemia effectively. Dietary restriction regimens, including fasting, have been considered for the prevention and treatment of certain solid tumor types. However, whether and how dietary restriction affects hematopoietic malignancies is unknown.
The study, performed by the authors of the technology, allowed to reveal that fasting alone robustly inhibits the initiation and reverses the leukemic progression of both B cell and T cell acute lymphoblastic leukemia, but not acute myeloid leukemia (AML), in mouse models of these tumors. Mechanistically, it was found that attenuated
These results indicate that the effects of fasting on tumor growth are
Practical application
Fasting, used in this technology, can serve as an effective therapy of B cell acute lymphoblastic leukemia at both the early and later stages of the disease in patients with de novo and relapsed acute lymphoblastic leukemia.
The technology will be valuable as a new method of acute lymphoblastic leukemia therapy and the study performed in process of its development will serve as a source of useful data for search of new treatment strategies for leukemia.
Laboratories
- Department of Physiology, University of Texas Southwestern Medical Center, Dallas (USA)
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (USA)
BMU-UTSW Joint Taishan Immunology Group, Binzhou Medical University, Yantai, Shandong (China)
Links
http://www.nature.com/nm/journal/v23/n1/full/nm.4252.htmlPublications
- Lu, Zh. Et al. «Fasting selectively blocks development of acute lymphoblastic leukemia via
leptin-receptor upregulation." 23 Nature Medicine, (2017): 79–90. - Kang, X. et al. «The
ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development." 17 Nat. Cell Biol. (2015): 665–677. - Zhang, C.C. et al. «
Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation." 111 Blood, (2008): 3415–3423.